LTS Lohmann Therapie-Systeme AG

LTS Lohmann Therapie-Systeme AG is a leading pharmaceutical technology partner, focusing on the development and manufacture of innovative drug delivery systems. With a diverse portfolio including Transdermal Patches (“TTS”), Oral Thin Films (“OTF”), and wearable drug delivery devices (“OBDS”), the company has more than 20 marketed products and over 40 development projects targeting various disease indications. Founded in 1984, LTS operates from four locations in Germany, the USA, and Israel, maintaining a representative office in China. The company's innovation pipeline, consisting of both partner-funded and proprietary projects, reflects its commitment to continuous refinement of core technologies and advancement in emerging drug delivery technologies, such as Micro Array Patches (“MAP”) for transdermal delivery of large molecule biological actives. Notably, LTS received a $4.30M grant investment in December 2023 from the Bill & Melinda Gates Foundation. With the SorrelTM wearable drug delivery platform, LTS provides patient-friendly solutions for complex drug delivery at home, underscoring its dedication to improving drug administration. As a key player in the biotechnology, healthcare, manufacturing, and pharmaceutical industries, LTS continues to demonstrate its commitment to innovation and patient care.